Breast Cancer

Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider can safely forgoing chemotherapy.

Companion Diagnostics

BRACAnalysis CDx^® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza^® (olaparib) and Zejula^® (niraparib).^1,2,3

 

myChoice^® HRD is a tumor test that can be used to guide important PARP inhibitor treatment decisions. By testing for BRCA1/2 status and Genomic Instability Status, which evaluates three downstream biomarkers associated with homologous recombination deficiency (HRD), myChoice HRD is capable of identifying more appropriate patients for PARP inhibitors than other biomarker assays.

Hereditary Cancers

Myriad myRisk^® Hereditary Cancer is a 28-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.

riskScore^TM is a clinically validated algorithm that predicts a women’s remaining 5-year and lifetime risk of developing breast cancer.

The BRACAnalysis ^® test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.

COLARIS^® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.

COLARIS AP ^® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.

MELARIS^® testing assesses a person’s risk of developing hereditary melanoma by detecting inherited mutations in the p16 gene (also called CDKN2A or INK4A ).

PANEXIA^® testing assesses a person’s risk of developing hereditary pancreatic cancer by analyzing the PALB2 and BRCA2 genes, which are most commonly mutated in families with hereditary pancreatic cancer.

Melanoma

Myriad myPath^® Melanoma measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.

Depression

GeneSight^® is a clinically proven test to enhance medication selection for healthcare providers, helping them get their patients on the right medications faster. Powered by CPGxTM, GeneSight is a proprietary combinatorial pharmacogenomics technology that analyzes how an individual’s genetic variations affect his or her response to medications and provides an actionable, easy to interpret report. GeneSight is used by healthcare providers to help patients that are affected by neuropsychiatric conditions including depression, anxiety, bipolar disorder, schizophrenia, ADHD, posttraumatic stress disorder (PTSD) and other behavioral health conditions, as well as chronic pain.

Prostate Cancer

Prolaris^® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris^® can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Rheumatoid Arthritis

Vectra^® DA is a multi-biomarker molecular blood test that simultaneously measures 12 key biomarkers to provide an objective and reproducible measure of rheumatoid arthritis (RA) disease activity.

 

Sources: